{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:02:04Z","timestamp":1795089724659,"version":"4.10.2"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Background and Aims:<\/jats:title>\n            <jats:p>We investigated whether empagliflozin reduces hepatic steatosis in patients with metabolic dysfunction\u2013associated steatotic liver disease without diabetes mellitus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Approach and Results:<\/jats:title>\n            <jats:p>This was an investigator-initiated, double-blind, randomized, placebo-controlled trial recruiting adult subjects from the community. Eligible subjects without diabetes mellitus (fasting plasma glucose &lt; 7 mmol\/L and HbA1c &lt; 6.5%) who had magnetic resonance imaging-proton density fat fraction (MRI-PDFF) \u2265 5% were randomly allocated to receive empagliflozin 10 mg daily or placebo (1:1 ratio) for 52 weeks (end of treatment, EOT). MRI-PDFF was conducted at baseline and EOT. The primary outcome was the difference in change of MRI-PDFF between the 2 groups at EOT. Secondary outcomes were hepatic steatosis resolution (MRI-PDFF &lt; 5%), alanine aminotransferase drop \u2265 17 U\/L, MRI-PDFF decline \u2265 30%, a combination of both, and changes of anthropometric and laboratory parameters at EOT. All outcomes were based on intention-to-treat analysis. Of 98 recruited subjects (median age: 55.7 y [IQR:49.5\u201363.4]; male:54 [55.1%]), 97 (empagliflozin:49, placebo:48; median MRI-PDFF:9.7% vs 9.0%) had MRI-PDFF repeated at EOT. The Empagliflozin group had a greater reduction in median MRI-PDFF compared to the placebo group (\u20132.49% vs. \u20131.43%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.025), with a nonsignificant trend of resolution of hepatic steatosis (44.9% vs. 28.6%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.094). There was no significant difference in alanine aminotransferase drop \u2265 17 U\/L (16.3% vs. 12.2%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.564), MRI-PDFF drop \u2265 30% (49.0% vs. 40.8%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.417), and composite outcome (8.2% vs. 8.2%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 1.000). Empagliflozin group had a greater drop in body weight (\u20132.7 vs. \u20130.2 kg), waist circumference (\u20132.0 vs. 0 cm), fasting glucose (\u20130.3 vs. 0 mmol\/L), and ferritin (\u2013126 vs. \u201322 pmol\/L) (all <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Empagliflozin for 52 weeks reduces hepatic fat content in subjects with nondiabetic metabolic dysfunction\u2013associated steatotic liver disease. (ClinicalTrials.gov Identifier: NCT04642261).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/hep.0000000000000855","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T13:05:05Z","timestamp":1711544705000},"page":"916-927","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":57,"title":["Effects of empagliflozin on liver fat in patients with metabolic dysfunction\u2013associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial"],"prefix":"10.1097","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-378X","authenticated-orcid":false,"given":"Ka Shing","family":"Cheung","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yu","family":"Ng","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rex Wan Hin","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lok Ka","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-3935","authenticated-orcid":false,"given":"Lung Yi","family":"Mak","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"},{"name":"Department of Medicine, Surgery, Pathology, Clinical Oncology and School of Biomedical Sciences, State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen Chi","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Radiology, Queen Mary Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Tong","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther W.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong"},{"name":"Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-313X","authenticated-orcid":false,"given":"Wai Kay","family":"Seto","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"},{"name":"Department of Medicine, Surgery, Pathology, Clinical Oncology and School of Biomedical Sciences, State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-7725","authenticated-orcid":false,"given":"Man Fung","family":"Yuen","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"},{"name":"Department of Medicine, Surgery, Pathology, Clinical Oncology and School of Biomedical Sciences, State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5993-1059","authenticated-orcid":false,"given":"Wai K.","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"R1-20250824","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R2-20250824","doi-asserted-by":"crossref","first-page":"100192","DOI":"10.1016\/j.jhepr.2020.100192","article-title":"NAFLD and liver transplantation: Disease burden, current management and future challenges","volume":"2","author":"Burra","year":"2020","journal-title":"JHEP Rep"},{"key":"R3-20250824","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R4-20250824","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cgh.2014.10.008","article-title":"Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile","volume":"13","author":"Siddiqui","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R5-20250824","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"R6-20250824","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2019.09.020","article-title":"Adipose tissue-associated cancer risk: Is it the fat around the liver, or the fat inside the liver?","volume":"71","author":"Marchesini","year":"2019","journal-title":"J Hepatol"},{"key":"R7-20250824","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/gutjnl-2020-321611","article-title":"Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"R8-20250824","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3350\/cmh.2022.0082","article-title":"Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients","volume":"28","author":"Cheung","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"R9-20250824","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R10-20250824","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jhep.2012.02.023","article-title":"Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"57","author":"Keating","year":"2012","journal-title":"J Hepatol"},{"key":"R11-20250824","doi-asserted-by":"crossref","first-page":"e0151511","DOI":"10.1371\/journal.pone.0151511","article-title":"Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction","volume":"11","author":"Komiya","year":"2016","journal-title":"PLoS One"},{"key":"R12-20250824","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"key":"R13-20250824","doi-asserted-by":"crossref","first-page":"e3413","DOI":"10.1002\/dmrr.3413","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials","volume":"37","author":"Coelho","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"R14-20250824","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.dld.2021.08.017","article-title":"The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis","volume":"54","author":"Mo","year":"2022","journal-title":"Dig Liver Dis"},{"key":"R15-20250824","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab"},{"key":"R16-20250824","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"R17-20250824","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-20250824","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/hep.26455","article-title":"Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials","volume":"58","author":"Noureddin","year":"2013","journal-title":"Hepatology"},{"key":"R19-20250824","doi-asserted-by":"crossref","first-page":"e001990","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): A randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"R20-20250824","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"R21-20250824","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"R22-20250824","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R23-20250824","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"R24-20250824","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/liv.12619","article-title":"High prevalence of non-alcoholic fatty liver disease in the Chinese - Results from the Hong Kong liver health census","volume":"35","author":"Fung","year":"2015","journal-title":"Liver Int"},{"key":"R25-20250824","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"key":"R26-20250824","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1148\/radiol.12120896","article-title":"Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis","volume":"267","author":"Tang","year":"2013","journal-title":"Radiology"},{"key":"R27-20250824","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R28-20250824","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0002-8223(96)00299-4","article-title":"Macronutrient and energy database for the 1995 Exchange Lists for Meal Planning: A rationale for clinical practice decisions","volume":"96","author":"Wheeler","year":"1996","journal-title":"J Am Diet Assoc"},{"key":"R29-20250824","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.24706","article-title":"Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease","volume":"55","author":"Kowdley","year":"2012","journal-title":"Hepatology"},{"key":"R30-20250824","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.cgh.2022.08.036","article-title":"Clinical utility of combined MRI-PDFF and ALT response in predicting histologic response in nonalcoholic fatty liver disease","volume":"21","author":"Huang","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R31-20250824","doi-asserted-by":"crossref","first-page":"i5078","DOI":"10.1136\/bmj.i5078","article-title":"Recommendations to improve adverse event reporting in clinical trial publications: A joint pharmaceutical industry\/journal editor perspective","volume":"355","author":"Lineberry","year":"2016","journal-title":"BMJ"},{"key":"R32-20250824","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/ijc.33379","article-title":"Calcium channel blockers are associated with lower gastric cancer risk: A territory-wide study with propensity score analysis","volume":"148","author":"Li","year":"2021","journal-title":"Int J Cancer"},{"key":"R33-20250824","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cld.1045","article-title":"Nonalcoholic fatty liver disease and recent guideline updates","volume":"17","author":"Ando","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"R34-20250824","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R35-20250824","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: A stage-based approach","volume":"13","author":"Rinella","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R36-20250824","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R37-20250824","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1515\/med-2018-0059","article-title":"Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease","volume":"13","author":"Miyake","year":"2018","journal-title":"Open Med (Wars)"},{"key":"R38-20250824","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-20250824","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"R40-20250824","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R41-20250824","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: A randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"R42-20250824","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: A Randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"R43-20250824","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"R44-20250824","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J Hepatol"},{"key":"R45-20250824","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1017\/S136898002200043X","article-title":"Personal motivation, self-regulation barriers and strategies for weight loss in people with overweight and obesity: A thematic framework analysis","volume":"25","author":"Chew","year":"2022","journal-title":"Public Health Nutr"},{"key":"R46-20250824","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1467-789X.2005.00170.x","article-title":"Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain","volume":"6","author":"Elfhag","year":"2005","journal-title":"Obes Rev"},{"key":"R47-20250824","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s42255-023-00864-1","article-title":"Differential mechanisms affecting weight loss and weight loss maintenance","volume":"5","author":"Rosenbaum","year":"2023","journal-title":"Nat Metab"},{"key":"R48-20250824","doi-asserted-by":"crossref","first-page":"e0146337","DOI":"10.1371\/journal.pone.0146337","article-title":"The Selective SGLT2 Inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice","volume":"11","author":"Honda","year":"2016","journal-title":"PLoS One"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HEP.0000000000000855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T22:05:04Z","timestamp":1756073104000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HEP.0000000000000855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/hep.0000000000000855","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"2023-12-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}